Standard Dose Weekly Intramuscular Beta Interferon-1a May Be Inadequate for Some Patients with Multiple Sclerosis: A 19-Year Clinical Experience Using Twice a Week Dosage

INTRODUCTION: Results from several clinical trials suggest there is a dose–response effect for beta interferon-1a (INFβ1a) in multiple sclerosis (MS). METHODS: Our objective was to confirm these results through a retrospective analysis of patients with MS who had breakthrough disease (BD) on intramu...

Descripción completa

Detalles Bibliográficos
Autores principales: Baumhefner, Robert W., Leng, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338207/
https://www.ncbi.nlm.nih.gov/pubmed/35796951
http://dx.doi.org/10.1007/s40120-022-00377-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338207/
https://www.ncbi.nlm.nih.gov/pubmed/35796951
http://dx.doi.org/10.1007/s40120-022-00377-1

Ejemplares similares